<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02841293</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/16/7940</org_study_id>
    <nct_id>NCT02841293</nct_id>
  </id_info>
  <brief_title>Cost-utility of Two Strategies of Perineal Reconstruction After Abdominoperineal Resection for Anorectal Carcinoma</brief_title>
  <acronym>GRECCAR-9</acronym>
  <official_title>Cost-utility Evaluation of Two Strategies of Perineal Reconstruction After Abdominoperineal Resection for Anorectal Carcinoma: Perineal Filling With Biological Meshes vs. Primary Perineal Wound Closure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Abdominoperineal resection performed for anorectal tumors leaves a large pelvic and perineal&#xD;
      defect causing a high rate of morbidity of the perineal wound (40 - 60 %). Biological meshes&#xD;
      offer possibility for a new standard of perineal wound reconstruction. Perineal filling with&#xD;
      biological mesh is expected to increase quality of life by reducing perineal morbidity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Perineal wound problems after abdominoperineal resection (APR) in the context of cancer are&#xD;
      frequent. These types of resection problems occur because of wound complications caused by&#xD;
      large perineal defects. Indeed, perineal wound complications, perineal abscess, wound&#xD;
      dehiscences, chronic fistulas and sinuses lengthen the hospital stays. Futhermore, the&#xD;
      standardization of the surgery since the late 2000s and the extralevator technique lead a&#xD;
      larger defect and increase i perineal complications.&#xD;
&#xD;
      Several strategies are used to decrease the complication rate. Closure by direct&#xD;
      approximation of the pelvic muscles leads to a rate of major complication up to 57% depending&#xD;
      on the series. Musculocutaneous flaps help to reduce this rate (16- 65%) but they generate&#xD;
      their own morbidity, require experience and increase the costs of care. Finally, the use of&#xD;
      biologic meshes since the beginning of 2010 seems to have improve the healing process.&#xD;
      However, results are still variable and the only randomized study comparing direct closure&#xD;
      and mesh closure showed no significant results at one year. Another ongoing randomized trial&#xD;
      is comparing gluteus maximus flap to mesh closure and focusing on physical performances.&#xD;
&#xD;
      This increase in post-operative complications and their consequences causes an increase in&#xD;
      costs. In addition, they affect the patients' quality of life and lead to a loss of&#xD;
      productivity. From an oncological point of view, perineal scarring problems can cause a delay&#xD;
      in the adjuvant therapeutic sequence. Few studies have highlighted the efficiency of perineal&#xD;
      wound complications, using cost-effectiveness analyses. In order to clarify the best strategy&#xD;
      comparing primary and mesh closure in term of cost effectiveness on perineal healing after&#xD;
      ELAPE, we designed this randomized controlled trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 7, 2021</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incremental Cost-Utility Ratio (ICUR)</measure>
    <time_frame>At 12 months</time_frame>
    <description>The primary endpoint in this study is based on the assessment of the incremental cost-utility ratio at 1 year, from the collective perspective between biological mesh perineal reconstructions versus. primary perineal closure in patients operated for anorectal carcinoma with proven rectal adenocarcinoma or anal canal epidermoid carcinoma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perineal wound healing</measure>
    <time_frame>At 1, 3, 6, 9 and 12 months</time_frame>
    <description>The perineal wound healing will be assessed using the Southampton wound assessment scale (6-point scale ranging from 0=normal healing to V=deep or severe wound infection)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain intensity</measure>
    <time_frame>From date of randomization until the date of study participation end of patient, assessed up to 12 months</time_frame>
    <description>assessed on an 11-point Numeric Rating Scale (NRS) at baseline before surgical procedure and at least 3 times a day during hospital stay. Thereafter, patients will rate their pain intensity in a patient subject diary every day and immediately before each use of pain medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related Quality of life</measure>
    <time_frame>1 month, 3 months, 6 months, 9 months, 12 months</time_frame>
    <description>Health related quality of life will be assessed using the EuroQOL EQ-5D-5L questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perineal complications</measure>
    <time_frame>Daily during hospitalization and at 1, 3, 6, 9 and 12 months after surgery</time_frame>
    <description>Perineal complications include:&#xD;
Perineal wound infection defined as a swelling of the wound or surrounding tissues with purulent discharge&#xD;
Breakdown of the perineal wound included any wound dehiscence, sinus or ulcer&#xD;
Pelvic abscess included a fluid collection in the pelvis&#xD;
Perineal evisceration defined by exposure of the pelvic cavity through the perineal wound&#xD;
Perineal hernia symptomatic or not&#xD;
Perineal sinus defined as an incomplete healing after 6 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Abdominoperineal Resection</condition>
  <arm_group>
    <arm_group_label>Arm with biological mesh</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention consists of perinal reconstruction using biological mesh (Cellis prosthesis from Meccellis Biotech, reference C1015E size 10x15cm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm with primary perineal wound closure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The intervention consists of perinal reconstruction by primary perineal wound closure</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biological mesh</intervention_name>
    <description>The intervention consists of suturing a biological mesh in the pelvic floor defect. The mesh will be sutured at each side of the coccyx or distal sacrum and directly to the residual pelvic floor muscle and fascia by using interrupted or continuous hand-sewn sutures with an appropriate amount of tension. The mesh that will be used is the Cellis prosthesis from Meccellis Biotech, reference C1015E which size is 10x15cm.</description>
    <arm_group_label>Arm with biological mesh</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Primary perineal wound closure</intervention_name>
    <description>The intervention consists of stitching the ischioanal and subcutaneous fat using interrupted Vicryl sutures in one or two layers similar to primary perineal closure</description>
    <arm_group_label>Arm with primary perineal wound closure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status score of 2 or less&#xD;
&#xD;
          -  Histologically proven rectal adenocarcinoma or anal canal epidermoïd carcinoma&#xD;
&#xD;
          -  Abdominoperineal resection indication after multidisciplinary team discussion:&#xD;
&#xD;
               -  for rectal adenocarcinoma: circumferential MRI margin equal or less than 1 mm&#xD;
                  from closest tumoral structure and a striated muscular layer (levator ani or&#xD;
                  external anal sphincter)&#xD;
&#xD;
               -  for epidermoid carcinoma: residual or recurrent tumour after chemoradiotherapy.&#xD;
&#xD;
          -  Voluntary written informed consent&#xD;
&#xD;
          -  Patients with social security insurance or equivalent social protection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  T4 tumour needing a surgical extensive resection with reconstruction by a&#xD;
             musculocutaneous flap&#xD;
&#xD;
          -  Metastasis disease deemed unresectable with curative intent&#xD;
&#xD;
          -  Previous pelvic radiotherapy for another disease than the rectal or anal cancer&#xD;
&#xD;
          -  Immunosuppressive drugs treatment&#xD;
&#xD;
          -  Uncontrolled diabetes (glycosylated hemoglobin (HbA1c) &gt; 8 % despite adequate therapy)&#xD;
&#xD;
          -  Patient under juridical protection.&#xD;
&#xD;
          -  Sensitivity to porcine derived products.&#xD;
&#xD;
          -  Enrolment in trial with overlapping primary endpoint.&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Breastfeeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Etienne BUSCAIL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Etienne BUSCAIL, MD</last_name>
    <phone>33-561322373</phone>
    <email>buscail.e@chu-toulouse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cindy CANIVET, CRA</last_name>
    <email>canivet.c@chu-toulouse.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Amiens University Hospital</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Marc REGIMBEAU</last_name>
      <email>regimbeau.jean-marc@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Marc REGIMBEAU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Angers University Hospital</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aurélien VENARA</last_name>
    </contact>
    <investigator>
      <last_name>Aurélien VENARA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Besançon University Hospital</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zaher LAKKIS</last_name>
      <email>zlakkis@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Zaher LAKKIS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bordeaux University Hospital</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Rullier</last_name>
      <email>eric.rullier@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Eric Rullier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Caen University Hospital</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arnaud ALVES</last_name>
      <email>alves-a@chu-caen.fr</email>
    </contact>
    <investigator>
      <last_name>Arnaud ALVES</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clermont-Ferrand University Hospital</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne DUBOIS</last_name>
      <email>A_dubois@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Anne DUBOIS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grenoble University Hospital</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bertrand TRILLING</last_name>
      <email>BTrilling@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Bertrand TRILLING</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehrdad JAFARI</last_name>
      <email>m-jafari@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Mehrdad JAFARI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guillaume PIESSEN, MD</last_name>
      <email>Guillaume.piessen@chru.lille.fr</email>
    </contact>
    <investigator>
      <last_name>Guillaume PIESSEN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lyon University Hospital</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eddy Cotte</last_name>
      <email>eddy.cotte@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Eddy Cotte</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paoli Calmettes Institut</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cécile De Chaisemartin</last_name>
      <email>dechaisemartin@ipc.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Cécile De Chaisemartin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cécilia CERIBELLI</last_name>
      <email>c.ceribelli@nancy.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Cécilia CERIBELLI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nancy University Hospital</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adeline GERMAIN</last_name>
      <email>a.germain@chru-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Adeline GERMAIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emilie DUCHALAIS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Emilie DUCHALAIS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint-Antoine Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jérémie LEFEVRE</last_name>
      <email>jeremie.lefevre@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Jérémie LEFEVRE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rouen University Hospital</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Jacques Tuech</last_name>
      <email>jean-jacques.tuech@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Jacques Tuech</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etienne Buscail, MD</last_name>
      <email>buscail.e@chu-toulouse.fr</email>
    </contact>
    <contact_backup>
      <last_name>Cindy Canivet, CRA</last_name>
      <email>canivet.c@chu-toulouse.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Etienne Buscail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 12, 2016</study_first_submitted>
  <study_first_submitted_qc>July 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2016</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anorectal carcinoma</keyword>
  <keyword>perineal filling</keyword>
  <keyword>cost-utility analysis</keyword>
  <keyword>biological meshes</keyword>
  <keyword>primary perineal wound closure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

